MOSCOW, February 10. /TASS/. Russia’s Vector State Research Center of Virology and Biotechnology submitted the results of the Phase One and Two clinical trials of the EpiVacCorona vaccine to foreign scientific journals, the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told reporters on Wednesday.
"The Vector State Research Center of Virology and Biotechnology has sent the results of the Phase One and Two vaccine clinical trials to foreign peer-reviewed scientific journals. The publication is expected in the near future," the sanitary watchdog’s press service stated.
The Russian sanitary watchdog emphasized that it was not "appropriate" to publish the results in the Russian-language scientific journals until the international publications were released. The main reason for this is "exclusivity and importance for a wide range of potential concerned parties".
"We assume that the content of these publications will shed light on the bulk of the scientific community’s questions," the press service noted.
On July 24, Russia’s Health Ministry authorized the Novosibirsk-based Vector State Research Center of Virology and Biotechnology to conduct the vaccine clinical trials on volunteers. The testing ended on September 30. On October 14, Russian President Vladimir Putin announced that Vector’s vaccine had been registered. Furthermore, on November 16 the Health Ministry granted permission for the EpiVacCorona post-registration studies on 150 volunteers aged over 60 years and on November 18 - for testing on 3,000 volunteers above 18 years of age.